Grifols SA ADR (GRFS) is a Healthcare · Drug Manufacturers - General company listed on NASDAQ. Price $7.31 (-1.22%), Market cap $5.28B, P/E ratio 10.78, 52-week low–high $7.49 ~ $10.85.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived
Financial statements, price targets, institutional (13F) holdings and related news for Grifols SA ADR are updated in real time on BlackAll Trade.
Grifols SA ADR trades at $7.31 (-1.22%). Real-time quotes and charts are available on BlackAll Trade.
Grifols SA ADR has a market cap of about $5.28B. Its P/E ratio is 10.78.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationa